Wegovy and Gallstones: What You Should Know Before Starting Treatment

Why does weight loss (including on Wegovy) raise the risk of gallstones?

The gallbladder stores bile, a digestive fluid the liver produces to break down dietary fat. When you lose weight quickly, the liver offloads more cholesterol into bile than usual, and bile movement slows because fat intake drops. Those two changes together (higher cholesterol concentration, less frequent emptying) create the conditions in which crystals form and eventually harden into stones.

This mechanism is not unique to semaglutide or GLP-1 medicines. It happens with bariatric surgery, very low-calorie diets, and any other intervention that produces brisk weight loss. What matters with Wegovy is that the medicine is effective enough to produce meaningful weight loss relatively quickly, so the gallstone risk that comes with that change is real and documented, and you can read more about it on our dedicated page covering Wegovy and gallstones.

Semaglutide also slows gastric emptying, a feature that reduces appetite but may also reduce the frequency of gallbladder contractions, meaning bile sits for longer. Researchers are still examining how much of the gallstone signal in trial data comes from the weight loss itself versus any direct effect of the medicine on the gallbladder. The current consensus leans towards weight loss as the primary driver, but the question is not fully settled.

The NHS medicines page for semaglutide lists gallbladder problems, including gallstones, among the side effects that should prompt medical attention.

What did the clinical trials actually find about semaglutide and gallstones?

A question our prescribers hear most weeks is some version of: "I've read that Wegovy causes gallstones, how likely is that really?" The STEP 1 trial, the pivotal 68-week study of semaglutide 2.4mg in adults with obesity, reported cholelithiasis in approximately 1.6% of participants on semaglutide versus 0.7% on placebo. That is a roughly doubled relative risk, but in absolute terms it means around one additional case per hundred people treated.

Across the broader STEP programme, gallbladder-related adverse events were more common on semaglutide than placebo, though serious events remained uncommon. The higher incidence tracked closely with the degree of weight loss achieved, reinforcing the view that it is the metabolic consequence of losing weight, rather than semaglutide acting directly on the gallbladder, that drives most of the risk.

For context, the background rate of gallstone formation in adults with obesity (the population Wegovy is licensed for) is already meaningfully elevated compared with the general population. The medicine increases that risk modestly rather than introducing it from nowhere. The STEP 1 trial paper, published in the New England Journal of Medicine, includes the full safety data for anyone who wants to read the primary source.

Losing weight more gradually may reduce the gallstone risk, one practical reason the titration schedule starts low and increases over several months, giving the body time to adjust.

Can you take Wegovy if you already have gallstones or gallbladder disease?

An existing diagnosis of gallstones, or a history of cholecystitis (gallbladder inflammation), does not automatically make semaglutide off-limits. It does mean the prescriber needs to know about it. The clinical assessment will consider factors like whether the gallstones are symptomatic, whether you've had previous episodes of biliary colic, and whether your gallbladder is still in place.

For people with asymptomatic gallstones discovered incidentally, many prescribers will proceed cautiously, with clear guidance about symptoms to watch for. For someone with a recent acute episode or active disease, the calculation is different. There is detailed guidance on this specific scenario at our page on taking Wegovy when you already have gallstones, and a related overview at what existing gallbladder disease means for Wegovy eligibility.

The short version: honesty in your consultation is what makes this work safely. If you have a gallbladder history, declare it. A prescriber can then make the right call rather than discovering the detail after something goes wrong. At nume, at nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber, not processed by software, so that kind of nuanced clinical history actually gets read.

Which symptoms mean you need medical help urgently?

If gallstones develop or become symptomatic on treatment, they tend to make themselves known. The classic presentation is biliary colic: sudden, cramping pain in the upper right abdomen, sometimes radiating to the right shoulder or shoulder blade, often after eating fatty food. It can last minutes or hours and usually resolves on its own, but that does not mean it should be ignored.

More urgent signs include fever alongside abdominal pain (suggesting infection, or cholecystitis), jaundice (yellowing of the skin or whites of the eyes) and very severe pain that does not ease. These are same-day emergency presentations; do not wait for a routine GP slot.

If you are on Wegovy and develop any of these, stop taking the medicine and seek medical attention promptly. Report suspected side effects through the MHRA Yellow Card scheme, it helps build the safety picture for everyone using these medicines.

Slowing the rate of weight loss, staying well hydrated, and not skipping meals entirely can all reduce gallstone risk during treatment. These are practical points worth discussing with your prescriber rather than adjusting unilaterally. For a broader overview of what Wegovy involves, including side effects beyond gallbladder concerns, the Wegovy treatment guide and the semaglutide overview cover the full picture. If you are considering starting and want to understand who supplies the medicine and what the dispensing process involves, our guide to Wegovy suppliers explains what to look for. If you want your clinical history properly reviewed, a free consultation with our prescribers is the right first step.